The primary analysis included 186 subjects who received the therapy and 139 subjects who were given a placebo.

Denali Therapeutics Inc. DNLI announced disappointing top-line results from an analysis of Regimen G of the phase II/III HEALEY ALS Platform Trial on pipeline candidate DNL343. The HEALEY platform ...

DNL343 showed no significant difference in ALSFRS-R scores or secondary endpoints compared to placebo over 24 weeks. Analysts await late-2025 data on biomarkers and subgroup findings for DNL343 ...

Massachusetts General Hospital found neither AbbVie and Calico’s fosigotifator nor Denali’s DNL343 significantly slowed disease progression, causing misses on their respective primary endpoints.

Denali Therapeutics Inc. (NASDAQ:DNLI) recently reported results from its phase 2/3 HEALEY ALS Platform Trial using DNL343 for the treatment of patients with Amyotrophic Lateral Sclerosis [ALS].

According to a press release from Denali Therapeutics Inc., the small molecule DNL343 was examined in the Healey ALS Platform study, whose primary endpoint was change in disease severity measured ...

Primary endpoint of overall function (ALSFRS-R) and survival, and key secondary endpoints of muscle strength and respiratory function, were not met at 24 weeks Overall, DNL343 was found to be safe and ...

Denali Therapeutics (DNLI) announced topline results from an analysis of Regimen G of the Phase 2/3 HEALEY ALS Platform Trial evaluating eIF2B agonist DNL343 in the treatment of amyotrophic ...

Denali Therapeutics Inc. DNLI announced disappointing top-line results from an analysis of Regimen G of the phase II/III HEALEY ALS Platform Trial on pipeline candidate DNL343. The HEALEY platform ...